Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Adaptimmune strikes $3 billion deal with Genentech to develop T cell therapies


29/11/2021 | 3 minutes to read

Copy link


Sanofi takes out Kadmon for $1.9 billion gaining transplant drug and IL-15 fusion protein

Sanofi has entered into a definitive merger agreement with Kadmon Holdings. The acquisition will immediately add Rezurock (belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy. Shareholders of Kadmon common stock will receive $9.50 per share in cash, which represents a total equity value of approximately $1.9 billion. Rezurock’s label could gain at least one additional indication. Data are due by year-end from an open-label Phase II trial of the therapy to treat systemic sclerosis. A separate placebo-controlled Phase 2 trial is also enrolling patients. Also in the pipeline lies anti-PD-L1/IL-15 fusion protein KD033, which is in Phase 1 testing for immuno-oncology.


Adaptimmune strikes $3+ billion deal with Genentech to develop cell therapies against cancer

Adaptimmune Therapeutics has entered into a strategic collaboration and license agreement with Genentech to develop and commercialize allogeneic cell therapies to treat multiple oncology indications. The collaboration has two components - development of allogeneic T-cell therapies for up to five shared cancer targets; and development of personalized allogeneic T-cell therapies. For each component, Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization. Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years, unless the agreement is earlier terminated. In addition, Adaptimmune may be eligible to receive research, development, regulatory and commercial milestones payments potentially exceeding $3 billion in aggregate value. Adaptimmune will also receive tiered royalties on net sales in the mid-single to low-double digits. Adaptimmune has the right to opt in to a 50/50 U.S. profit/cost share on "off-the-shelf" products. If Adaptimmune elects to opt in, then Adaptimmune will be eligible to share 50 percent of profits and losses from U.S. sales on such products and is eligible to receive ex-US regulatory and sales-based milestone payments, as well as royalties on ex-US net sales.

Tiziana Life Sciences and Precision Bio to evaluate foralumab to improve CAR-T outcomes

Tiziana Life Sciences and Precision BioSciences to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR-T cells to potentially improve the clinical outcome of CAR-T cell therapy. Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties for foralumab.

Twist and Adicet to discover and develop gamma delta T cells

Twist Bioscience is continuing its run of therapeutic discovery deals, announcing a new collaboration with Adicet Bio to discover and develop allogeneic γδ T cell therapies for cancer and other indications. The partners will discover and develop γδ T cells expressing CARs or TCRs against five undisclosed targets by combining Twist’s Library of Libraries for identification of target-specific binders using its single chain fragment variable (scFv) and VHH (nanobody) technologies, and Adicet’s CAR engineering and discovery capabilities. Twist will receive an upfront technology licensing fee for each program, plus milestones and royalties. Last week, Twist announced an antibody discovery deal with Boehringer Ingelheim.

Overview of transactions in oncology (values in m$)









Genfleet Therapeutics

Innovent Biologics

Small molecule KRAS G12C inhibitor against KRAS G12C solid tumors

Ph 1/2

CN,HK, TW,MC,ww opt.




Adaptimmune Therapeutics


Allogenic T cell therapies to treat cancer using iPSC-derived allogenic cell therapy platform



3300 150 3150

NASDAQ Initial Public Offerings (IPOs) in oncology



Lead product



Amount m$

Price $

Tyra  Biosciences



Selective inhibitor of FGFR3 against bladder cancer and solid tumors




Share on social networks

Share on social networks


Copy link